Dinners · AI and the commercial side of pharma

Twelve people.
One table.
No slides.

An invitation-only dinner series on AI and its impact on the commercial side of pharma — for the people who scout, evaluate, license and launch drugs, and the people building the tools they use. Chatham House rule throughout.

$499 per seat. Dinner included; twelve seats per table.

Proudly Sponsored By

Become a Sponsor →

Why we gather

Innovators in AI and in pharma, at the same table.

Every medicine that reaches a patient was once a decision somebody had to make with incomplete information — which asset to pursue, which to pass on, which market to launch in first. These dinners bring together the people building artificial intelligence and the people making those decisions: founders and researchers alongside business development, search and evaluation, competitive intelligence and commercial leaders, and the investors behind them.

The aim is practical. Shorten the distance between a model that works and a medicine that ships. Use AI to accelerate discovery, sharpen evaluation and get treatments to the people who need them sooner.

Cure more. Waste less. Move faster, together.

The series

Three cities, two tables each.

The dinner schedule is for invited guests.

How they run

No agenda, no podium.

We open with introductions — who you are and what you are working on — and then the host keeps the table on the evening's theme. Nobody presents. Nobody pitches. If a vendor is at the table they are there as a participant, and the room is told who they are.

Seats are single-role where we can manage it, so that nobody at the table is selling to anybody else at the table.

We write up what was argued, never who said it, and send it only to the people who were there.

Request a seat — $499.

Twelve seats per table. Tell us which city and we will come back as the dates firm up. Attending from a pharma company? The seat value is stated on the invoice so you can clear it with compliance.